Preferred Label : CDK7 Inhibitor TY-2699a;
NCIt definition : An orally bioavailable inhibitor of cyclin-dependent kinase 7 (CDK7), with potential
antineoplastic activity. Upon oral administration, CDK7 inhibitor TY-2699a selectively
targets, binds to and inhibits the activity of CDK7, thereby inhibiting CDK7-mediated
signaling. The inhibition of CDK7 prevents phosphorylation of the carboxy-terminal
domain (CTD) of RNA polymerase II, thereby preventing transcription of important cancer-promoting
genes. The inhibition of CDK7 also prevents the phosphorylation of the cell cycle
kinases CDK1, 2, 4, and 6, thereby disrupting uncontrolled cell cycle progression.
Altogether, this may induce apoptosis, cause cell cycle arrest, inhibit DNA damage
repair and inhibit tumor cell proliferation in certain cancers that are dependent
on CDK7-mediated transcriptional regulation and signaling. CDK7, a serine/threonine
kinase, plays a role in controlling cell cycle progression and transcriptional regulation,
and promotes the expression of key oncogenes through the phosphorylation of RNA polymerase
II. It is overexpressed in multiple cancers.;
Molecule name : TY 2699a; TY-2699a;
Origin ID : C200816;
concept_is_in_subset
- has_target
